Innate : First Patient Dosed In IPH6101/SAR443579 Phase 1/2 Trial In Various Blood Cancers
16/12 07:18
(RTTNews) - Innate Pharma SA (IPHA) said that the first patient was dosed in a Phase 1/2 clinical trial (NCT05086315), evaluating IPH6101/SAR443579, the first NKp46/CD16-based NK cell engager, in patients with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute...